Latest News

Endocannabinoid System
SYT-510: First-in-Class Inhibitor Targets Endocannabinoid System to Improve Mental Health Outcomes

September 24th 2025

Synendos Therapeutics reveals promising phase 1 results for SYT-510, a novel ECS modulator targeting anxiety and CNS disorders with potential for improved patient outcomes.

lumateprone caplyta major depressive disorder anxious distress
Phase 3 Study of Lumateperone as Adjunct to Antidepressant Therapy for Major Depressive Disorder and Anxious Distress Meets End Points

September 21st 2025

cannabidiol CBD crystal
New Preclinical Data on ART12.11 for the Treatment of Mood and Anxiety Disorders

September 10th 2025

social anxiety
Target Enrollment Completed for Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder

September 4th 2025

psychedelic
Positive Phase 2 Results: Psilocybin-Assisted Psychotherapy Treatment, PSX-001, for Generalized Anxiety Disorder

August 26th 2025

Video Interviews
Podcasts
Latest CME Events & Activities

More News

© 2025 MJH Life Sciences

All rights reserved.